Pfizer, Mylan Await Decision In Norvasc Patent Case
After a seven-day bench trial, attorneys for Pfizer Inc. and generic drug maker Mylan Pharmaceuticals Inc. made closing arguments Wednesday, putting the final touch on a longstanding patent infringement suit over...To view the full article, register now.
Already a subscriber? Click here to view full article